Protalix BioTherapeutics to Present at Three International Healthcare Conferences.
The conference schedule is as follows:
About Protalix BioTherapeutics
Protalix is a biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based expression system. Protalix's ProCellEx(TM) presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix is enrolling and treating patients in its pivotal phase III clinical trial in Israel, the United States and other locations for its lead product candidate, prGCD, for its enzyme replacement therapy for Gaucher disease, a lysosomal storage disorder in humans, and has reached an agreement with the United States Food and Drug Administration on the final design of the pivotal phase III clinical trial through the FDA's Special Protocol Assessment (SPA) process. Protalix is also advancing additional recombinant biopharmaceutical drug development programs.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Conference news|
|Date:||May 23, 2008|
|Previous Article:||Media Breakaway, LLC Announces Next Community Involvement Initiative.|
|Next Article:||Safe Riding Tips from the ATV Safety Institute as Summer Riding Season Begins this Holiday Weekend.|